SGPGI study of 6,093 pulmonary sarcoidosis patients finds 39% relapse after stopping treatment, highest risk 6–12 months; follow-up crucial, often mistaken for TB.
Among adults with both obesity and an autoimmune disease, those taking a glucagon-like peptide-receptor 1 agonist (GLP-1RA) ...
An international research team has succeeded in elucidating key immunological and biochemical mechanisms underlying ...
Hoffmann won a $50,000 research grant to search for a cure to Facioscapulohumeral Muscular Dystrophy, or FSHD, a disease she ...
Unprecedented results against a stubbornly hard-to-treat cancer are boosting optimism that other challenging tumors will be ...
IgG4-related disease is a chronic fibroinflammatory condition that can affect virtually any organ system. Glucocorticoid agents are a cornerstone of therapy but are limited by toxic effects, and ...
At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of ...
AstraZeneca’s IMFINZI ® (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy has been approved in the US for the treatment of adult patients with BCG-naïve ...
Inside Fleur Marks’ extraordinary story of burnout, illness and survival, and how she learned to “show up for life” despite ...
The United States is a world leader in gun violence, far surpassing other high-income nations like Chile, Canada, and Portugal. Given the sheer number of guns in the United States — 121 firearms for ...
Dr Anjali Pathak on how granuloma annulare may be overlooked and how to identify and manage this unusual skin condition ...
IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results